|
ACB Blocks' Fragment Library
We have recently finished designing a special NMR-directed fragment library
of 1280 small drug-like compounds fitting strict NMR-&-Ro3 fragment
criteria. Listed below are the basic characteristics of the resulted product:
1. All compounds are drug-like privileged structures. The selection
of such specific fragments was based on the methodology of identification
of privileged substructures.
2. The compounds are highly diverse, especially in the sense of
"heterocyclicdiversity. Each compound may be used as a precursor
for building up sub-libraries that can be explored in further experiments.
*
3. There are several dispersed proton signals in the NMR spectrum
of each compound and all structures are stereo-defined.
4. All compounds satisfy Ro3 criteria:
Compounds are small - MW <300 (Ro3: MW
< 330), average MW=214
Compounds typically have:
1-3 rings (Ro3: < 3);
1-5 rotatable bonds (Ro3: < 6), average
2.16
1-3 donors of hydrogen bonds (Ro3: <
3), average 1.66
1-5 acceptors of hydrogen bonds (Ro3: between
1 and 6), average 3.03
|
|
 Molecular weight
 LogP
 LogSw
 Number of rotatable bonds
 Number of hydrogen bond donors
 Number of hydrogen bond acceptors
5. Compounds are non-aggregative.
6. Purity of fragments is more than 96% (LCMS, NMR).
7. Compounds are non-reactive. About 100 special filters were
applied for elimination of compounds with unwanted functionality (NO2,
SH, hydrazones, epoxides, alkylating agents, Michael acceptors, redox,
etc.)
8. Compounds are polar and non-lipophylic. ClogP < 5.0 for
all the selected compounds (average 2.03) and for 958 compounds ClogP
< 3.0 (Ro3: ClogP < 3.0). These results are obtained with ALOGPC
program. **, ***
9. Compounds should prove soluble in D2O. Solubility predicted
with ALOGPC software seems very promising, as all compounds have ClogSW
> -5.00; 1150 compounds have ClogSW > - 4.00; for 808 compounds
the calculated solubility is more than 1.0 mM (ClogSW > -3.00).
We expect the proposed library to be an extremely powerful tool for NMR
/ X-Ray / MS-based drug discovery.
* N. Baurin, F. Aboul-Ela, X. Barril, B. Davis, M. Drysdale, B. Dymock,
H. Finch, C. Fromont, C. Richardson, H. Simmonite, R.E. Hubbard J. Chem.
Inf. Comput. Sci. 2004, 44, 2157-2166.
** I. Tetko, P. Bruneau Journal of Pharmaceutical Sciences, 2004, v. 93,
12, 3103-3110
*** Igor V. Tetko, and Gennadiy I. Poda J. Med. Chem. 2004, 47, 5601-5604
|